Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design
- 1 February 2022
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 229, 114043
Abstract
No abstract availableKeywords
Funding Information
- Taiwan Ministry of Science and Technology
- National Health Research Institutes (BP-105-PP-01, BP-106-PP-01)
- Taiwan Ministry of Health and Welfare (MOHW103-TDU-212-114006)
This publication has 39 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic PerspectivesClinical Cancer Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematologyBlood, 2009
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005
- Synergistic Transcriptional Activation of Indoleamine Dioxygenase by IFN-γ and Tumor Necrosis Factor-αJournal of Interferon & Cytokine Research, 2003
- Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell divisionImmunology, 2002
- Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-DioxygenaseJournal of Experimental Medicine, 2002
- Potentiation of Interferon-Induced Indoleamine 2,3-Dioxygenase mRNA in Human Mononuclear Phagocytes by Lipopolysaccharide and Interleukin-1Journal of Interferon & Cytokine Research, 1997